NASDAQ:APRE

Aprea Therapeutics News Headlines

$4.19
-0.06 (-1.41 %)
(As of 08/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.12
$4.38
50-Day Range
$4.15
$5.63
52-Week Range
$3.88
$31.45
Volume487,625 shs
Average Volume2.25 million shs
Market Capitalization$88.77 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.02

Aprea Therapeutics (NASDAQ APRE) News Headlines Today

SourceHeadline
Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Decline in Short InterestAprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Decline in Short Interest
americanbankingnews.com - July 30 at 4:48 AM
Aprea Therapeutics Shares Rise 7% on Positive Data for Eprenetapopt TrialAprea Therapeutics Shares Rise 7% on Positive Data for Eprenetapopt Trial
marketwatch.com - July 22 at 9:07 AM
Karolinska Development’s portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapoptKarolinska Development’s portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt
finance.yahoo.com - July 22 at 9:07 AM
Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-TransplantAprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant
finance.yahoo.com - July 21 at 10:57 PM
BRIEF-Aprea Therapeutics Announces Positive Results From Trial Of Eprenetapopt + AzacitidineBRIEF-Aprea Therapeutics Announces Positive Results From Trial Of Eprenetapopt + Azacitidine
msn.com - July 21 at 12:56 PM
Analyzing Aprea Therapeuticss Unusual Options ActivityAnalyzing Aprea Therapeutics's Unusual Options Activity
benzinga.com - July 21 at 12:56 PM
Aprea Therapeutics Climbs 3% On Positive Study Results Of Its Lead DrugAprea Therapeutics Climbs 3% On Positive Study Results Of Its Lead Drug
markets.businessinsider.com - July 21 at 12:56 PM
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AMLAprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
finance.yahoo.com - July 21 at 12:56 PM
Traders Buy High Volume of Call Options on Aprea Therapeutics (NASDAQ:APRE)Traders Buy High Volume of Call Options on Aprea Therapeutics (NASDAQ:APRE)
americanbankingnews.com - July 21 at 11:04 AM
Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Growth in Short InterestAprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Growth in Short Interest
americanbankingnews.com - July 19 at 4:38 AM
Aprea Therapeutics, Inc. (NASDAQ:APRE) Receives Average Rating of "Hold" from AnalystsAprea Therapeutics, Inc. (NASDAQ:APRE) Receives Average Rating of "Hold" from Analysts
americanbankingnews.com - July 14 at 10:12 AM
Implied Volatility Surging for Aprea (APRE) Stock OptionsImplied Volatility Surging for Aprea (APRE) Stock Options
finance.yahoo.com - June 18 at 9:50 AM
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study GoalAprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
finance.yahoo.com - June 17 at 12:28 PM
Aprea Therapeutics Shares Rise 18% on Trial for Leukemia TreatmentAprea Therapeutics Shares Rise 18% on Trial for Leukemia Treatment
marketwatch.com - June 16 at 3:31 PM
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia PatientsAprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
finance.yahoo.com - June 16 at 3:31 PM
Aprea : Phase 1/2 Trial On TP53 Mutant AML Meets Complete Remission Primary Efficacy EndpointAprea : Phase 1/2 Trial On TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
markets.businessinsider.com - June 16 at 10:31 AM
Aprea Therapeutics Sees Positive Results in Trial for Leukemia TreatmentAprea Therapeutics Sees Positive Results in Trial for Leukemia Treatment
marketwatch.com - June 16 at 10:31 AM
Why Aprea Therapeutics Shares Are Surging TodayWhy Aprea Therapeutics Shares Are Surging Today
benzinga.com - June 16 at 10:31 AM
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy EndpointAprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
finance.yahoo.com - June 16 at 10:31 AM
Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy?Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy?
finance.yahoo.com - June 13 at 1:15 PM
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth?Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth?
finance.yahoo.com - June 4 at 8:58 AM
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease SummitAprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
finance.yahoo.com - May 21 at 8:26 AM
Aprea Therapeutics, Inc. Common stock (APRE)Aprea Therapeutics, Inc. Common stock (APRE)
nasdaq.com - May 11 at 12:19 AM
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business OperationsAprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
finance.yahoo.com - May 6 at 5:52 PM
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
finance.yahoo.com - April 16 at 12:48 PM
Karolinska Development’s portfolio company Aprea Therapeutics receives orphan drug designation for eprenetapopt in AMLKarolinska Development’s portfolio company Aprea Therapeutics receives orphan drug designation for eprenetapopt in AML
finance.yahoo.com - April 9 at 8:56 AM
What Type Of Shareholders Make Up Aprea Therapeutics, Inc.s (NASDAQ:APRE) Share Registry?What Type Of Shareholders Make Up Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Share Registry?
nasdaq.com - April 7 at 10:16 PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business OperationsAprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
finance.yahoo.com - March 16 at 7:11 PM
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to BuyAll You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
nasdaq.com - February 23 at 2:49 PM
Assessing Aprea TherapeuticsAssessing Aprea Therapeutics
seekingalpha.com - February 18 at 12:11 AM
Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions?Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions?
finance.yahoo.com - February 16 at 6:53 PM
What Makes Aprea Therapeutics, Inc. (APRE) a New Buy StockWhat Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock
finance.yahoo.com - January 22 at 2:37 PM
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
finance.yahoo.com - January 8 at 12:03 PM
Aprea Therapeutics Inc Registered Shs Sector PerformAprea Therapeutics Inc Registered Shs Sector Perform
markets.businessinsider.com - December 31 at 12:14 AM
RBC Capital Downgrades Aprea Therapeutics to Sector Perform, Lowers Price Target to $10RBC Capital Downgrades Aprea Therapeutics to Sector Perform, Lowers Price Target to $10
benzinga.com - December 31 at 12:14 AM
Don’t Go Bargain Hunting on Aprea Stock, Says AnalystDon’t Go Bargain Hunting on Aprea Stock, Says Analyst
finance.yahoo.com - December 30 at 12:22 AM
Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet GoalAprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
finance.yahoo.com - December 29 at 2:21 PM
Aprea Shares Slump After Cancer-Drug Trial Misses Key GoalAprea Shares Slump After Cancer-Drug Trial Misses Key Goal
thestreet.com - December 28 at 5:55 PM
Stock Alert: Aprea Tanks 80% After Blood Cancer Drug Trial Fails To Meet Main GoalStock Alert: Aprea Tanks 80% After Blood Cancer Drug Trial Fails To Meet Main Goal
nasdaq.com - December 28 at 12:55 PM
Mid-Day Market Update: Dow Surges 240 Points; Aprea Therapeutics Shares PlungeMid-Day Market Update: Dow Surges 240 Points; Aprea Therapeutics Shares Plunge
markets.businessinsider.com - December 28 at 12:55 PM
Is Aprea Therapeutics Doomed?Is Aprea Therapeutics Doomed?
msn.com - December 28 at 12:55 PM
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
finance.yahoo.com - December 28 at 12:55 PM
Can Eprenetapopt Data Help Reverse Course Of Aprea Therapeutics Stock?Can Eprenetapopt Data Help Reverse Course Of Aprea Therapeutics' Stock?
nasdaq.com - December 21 at 7:14 AM
Aprea Therapeutics Inc Registered Shs Equal WeightAprea Therapeutics Inc Registered Shs Equal Weight
markets.businessinsider.com - December 17 at 11:18 PM
Aprea Therapeutics Inc Registered Shs BuyAprea Therapeutics Inc Registered Shs Buy
markets.businessinsider.com - December 17 at 11:18 PM
Is APRE A Good Stock To Buy Now?Is APRE A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 11:31 PM
Karolinska Developments portfolio company Aprea Therapeutics receives FDA Fast Track designation for eprenetapopt in AMLKarolinska Development's portfolio company Aprea Therapeutics receives FDA Fast Track designation for eprenetapopt in AML
uk.finance.yahoo.com - November 30 at 3:19 PM
Apreas eprenetapopt Fast Trackd for type of blood cancerAprea's eprenetapopt Fast Track'd for type of blood cancer
seekingalpha.com - November 30 at 9:57 AM
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
finance.yahoo.com - November 30 at 9:57 AM
Aprea Therapeutics Inc.Aprea Therapeutics Inc.
barrons.com - November 28 at 8:33 PM
This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.